The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Ellipses Pharma (Inst); Inovio Pharmaceuticals; Merck (Inst); Regeneron
Research Funding - Abbvie (Inst); Aduro Biotech (Inst); Advaxis (Inst); Aeterna Zentaris (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Cerulean Pharma (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Millennium (Inst); Morab (Inst); Morphotek (Inst); Novartis (Inst); Pfizer (Inst); Syndax (Inst); Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - Editor, British Journal of Ob/Gyn; UpToDate
Phase II dose optimization with EZH2/EZH1 inhibitor tulmimetostat in patients (pts) with advanced solid tumors or hematologic malignancies.
 
Ana Oaknin
Consulting or Advisory Role - AGENUS; AstraZeneca; Clovis Oncology; Corcept Therapeutics; Daiichi Sankyo; Debiopharm Group; Deciphera; Eisai; Exelixis; Genmab; GlaxoSmithKline; Immunogen; ITeos Therapeutics; Merck Sharp & Dohme; Mersana; Myriad Genetics; Novocure; OneXerna Therapeutics, Inc.; PharmaMar; Regeneron; Roche; Seagen; Shattuck Labs; Sutro Biopharma; Zentalis
Research Funding - Abbvie (Inst); Advaxis (Inst); Aeterna Zentaris (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Bristol-Myers Squibb International Corporation (BMS) (Inst); Clovis Oncology (Inst); Eisai (Inst); Immunogen (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); PharmaMar (Inst); Regeneron (Inst); Roche (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; PharmaMar; Roche
 
Kalyan Banda
Honoraria - GlaxoSmithKline; Immunogen
Research Funding - Kineta (Inst); Lilly (Inst); MorphoSys (Inst); Pfizer (Inst); Regeneron (Inst)
 
Charles Drescher
Leadership - Powell-Drescher Ovarian Cancer Research Foundation; Rivkin Center; Swedish Cancer Institute
Research Funding - Canary Foundation; NCI
 
Vincent Ribrag
Honoraria - Abbvie; AZD; Gilead Sciences; Infinity Pharmaceuticals; NanoString Technologies; Novartis; roche
Consulting or Advisory Role - Bristol-Myers Squibb; Gilead Sciences; Immune Design; Incyte; Infinity Pharmaceuticals; MSD; NanoString Technologies; PharmaMar; Roche; Roche/Genentech
Research Funding - arGEN-X BVBA; argenx (Inst); Astex Pharmaceuticals (Inst); Epizyme (Inst); GlaxoSmithKline/Adaptimmune (Inst)
Expert Testimony - SERVIER
Travel, Accommodations, Expenses - azd; AZD; Bristol-Myers Squibb; Bristol-Myers Squibb; Roche
 
Hedy L. Kindler
No Relationships to Disclose
 
Harriet S. Walter
Honoraria - AstraZeneca; BeiGene; Genmab; Loxo
Consulting or Advisory Role - BeiGene; Genmab; Loxo
Research Funding - Gilead Sciences; Pfizer
 
Alok Tewari
Stock and Other Ownership Interests - B.A.I. Biosciences; Moderna Therapeutics; Teladoc
Honoraria - UroToday
Consulting or Advisory Role - Best Doctors, Inc
 
Elvire Pons-Tostivint
Consulting or Advisory Role - AstraZeneca; Sanofi Pasteur; Takeda
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Sanofi; Takeda
 
Nehal J. Lakhani
Research Funding - Alexo Therapeutics (Inst); Alkermes (Inst); Alkermes/Mural Oncology (Inst); Alpine Immune Sciences (Inst); Alpine Immune Sciences (Inst); Apexian Pharmaceuticals (Inst); Arcus Ventures (Inst); Artios (Inst); Ascentage Pharma (Inst); Astellas Pharma (Inst); BeiGene (Inst); BioNTech SE (Inst); Biosplice (Inst); Celgene (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Coordination Therapeutics (Inst); CytomX Therapeutics (Inst); Epizyme (Inst); Forty Seven (Inst); Genmab (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Helsinn Therapeutics (Inst); Ikena Oncology (Inst); Ikena Oncology (Inst); Incyte (Inst); InhibRx (Inst); Innovent Biologics (Inst); Janssen (Inst); Jounce Therapeutics (Inst); KSQ Therapeutics (Inst); LAM Therapeutics (Inst); Lilly (Inst); Livzon (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); Northern Biologics (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Sapience Therapeutics (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Servier (Inst); Shattuck Labs (Inst); SK Life Sciences (Inst); Symphogen (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst)
 
R. Donald Harvey
Consulting or Advisory Role - EMD Serono; Janssen Oncology; Ribometrix
Research Funding - Janssen Research & Development (Inst); Meryx Pharmaceuticals (Inst); MorphoSys
 
Ryan J. Sullivan
Consulting or Advisory Role - Bristol-Myers Squibb; maren; Merck; Novartis; Pfizer; Replimune
Research Funding - Aeglea Biotherapeutics (Inst); Amgen (Inst); Asana Biosciences (Inst); BeiGene (Inst); BioMed Valley Discoveries (Inst); Compugen (Inst); Deciphera (Inst); Lilly (Inst); Marengo Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Neon Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Strategia (Inst); Strategia (Inst); Synthekine (Inst); Viralytics (Inst)
 
Pier Luigi Zinzani
Consulting or Advisory Role - ADC Therapeutics; BeiGene; Bristol-Myers Squibb; Celltrion; EUSA Pharma; Gilead Sciences; Incyte; Janssen-Cilag; Kyowa Hakko Kirin; MSD; Novartis; Roche; Sandoz; Secura BIO; SERVIER; Takeda; TG Therapeutics
Speakers' Bureau - EUSA Pharma; MSD; Novartis
 
Antonio Gonzalez Martin
Consulting or Advisory Role - Alkermes; Amgen; AstraZeneca; Clovis Oncology; Genmab; Hedera Dx; Immunogen; Kartos Therapeutics; Macrogenics; Mersana; MSD; Novartis; Novocure; Oncoinvent; Pfizer/EMD Serono; Roche; Seagen; SOTIO; Sutro Biopharma; Takeda; Tesaro/GSK; Tubulis GmbH
Speakers' Bureau - AstraZeneca; Clovis Oncology; MSD Oncology; PharmaMar; Roche; Tesaro/GSK
Research Funding - Roche (Inst); Tesaro/GSK (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD Oncology; PharmaMar; Roche; Tesaro/GSK
 
Lauriane Eberst
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline
 
Luis Manso Sánchez
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Lilly; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Tesaro
Speakers' Bureau - AstraZeneca; Lilly; Novartis; Pfizer; Roche/Genentech
Research Funding - Tesaro
Travel, Accommodations, Expenses - GlaxoSmithKline; MSD Oncology; Novartis; Roche/Genentech; Tesaro
 
Anjali Thakur
Employment - MorphoSys
 
Lennart Kann
Employment - MorphoSys
 
Archana Reddy
Employment - MorphoSys
 
Nicola Faulhaber
Employment - MorphoSys
 
Linda Duska
No Relationships to Disclose